PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.\', \'Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.\', \'Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.\', \'Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America. Electronic address: glutty@jhmi.edu.\', \'Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Department of Chemical and Biomolecular Engineering, Johns Hopkins University, Baltimore, MD, United States of America. Electronic address: krangar1@jhmi.edu.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • S0168-3659(21)00260-110.1016/j.jconrel.2021.05.035
?:hasPublicationType
?:journal
  • Journal of controlled release : official journal of the Controlled Release Society
is ?:pmid of
?:pmid
?:pmid
  • 34058271
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Systemic dendrimer nanotherapies for targeted suppression of choroidal inflammation and neovascularization in age-related macular degeneration.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all